1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

 
• By Alaric DeArment

IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.

Blue and purple graphic image of pair of kidneys
• Source: Shutterstock

In the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to segment IgAN patients and which drug to use – a question that even nephrologists are having difficulty answering – and what challenges in the disease and its treatment they must still seek to address.

Two significant developments in the field happened in the last few months of 2024. On 5 September, the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Market Snapshot

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

 
• By Mandy Jackson

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

 
• By Mandy Jackson

Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors

 
• By Mandy Jackson

The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.